StockData

Castle Biosciences vs Exagen

CSTL and XGN side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CSTL and XGN compare

Castle Biosciences is the larger company, worth 11 times as much as Exagen ($1.0B against $91.1M).

Exagen grew revenue faster over the last twelve months (20.8% versus 9.8% for Castle Biosciences).

Castle Biosciences keeps more of each dollar of sales as profit, with a net margin of −6.1% compared with −26.6% at Exagen.

Castle Biosciences scores higher on the StockData Score (11 against 5 for Exagen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCSTLXGN
Size and price
Market cap$1.0B$91.1M
Share price$32.98$3.76
Change, 1 year−1.4%−58.3%
Change, 5 years−23.5%−65.9%
Beta (5Y)0.682.77
Employees883220
StockData Score
Total score11 (better)5
Valuation score2 (better)0
Growth score23 (better)
Performance score3 (better)1
Health score4 (better)1
Dividend score00
Valuation
P/S2.7×1.3× (better)
P/B2.1× (better)7.5×
P/FCF254×–
FCF yield0.39% (better)−8.3%
Fair value$34.22$3.42
Margin of safety3.6% (better)−9.9%
Growth
Revenue growth (TTM)9.8%20.8% (better)
Revenue growth, 5Y average40.6% (better)9.7%
Profitability
Gross margin77.1% (better)58.6%
Operating margin−7.4% (better)−18.6%
Net margin−6.1% (better)−26.6%
FCF margin1.1% (better)−10.7%
Return on equity−4.9% (better)−114%
Return on invested capital−11.1% (better)−86.1%
Financial health
Debt / equity0.02 (better)1.87
Interest coverage−51.2×−2.6× (better)
Current ratio5.28 (better)3.18
Altman Z-score6.49 (better)−6.08
Piotroski F-score44
Dividends and buybacks
Dividend yield0.00%–
Years of dividend growth0–
Shareholder yield0.00%0.00%
Ownership
Held by institutions89.5%34.1%
Held by insiders1.9%29.2%
Insider net buying, 12 months−$18.4M−$769K (better)
Short interest, % of float7.0%4.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.